Search

Your search keyword '"Dale L. Bixby"' showing total 3 results
Start Over Author "Dale L. Bixby" Publisher harborside press, llc
3 results on '"Dale L. Bixby"'

1. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Author

Daniel A. Pollyea, Matthew J. Wieduwilt, Pankit Vachhani, Ivana Gojo, Dinesh S. Rao, Alice S. Mims, Dale L. Bixby, Jessica K. Altman, Alexander E. Perl, Jeffrey E. Lancet, Reza Nejati, Paul J. Shami, Richard Stone, Aric C. Hall, Mary Elizabeth Percival, Guido Marcucci, Kristina M. Gregory, Frederick R. Appelbaum, Jadee L. Neff, Gabriel N. Mannis, Meagan A. Jacoby, Farhad Ravandi-Kashani, Marcos de Lima, Rebecca L. Olin, James M. Foran, Martin S. Tallman, Stephen A. Strickland, Amir T. Fathi, Kendra Sweet, Amanda Przespolewski, Michael Gary Martin, Thomas Prebet, Vijaya Raj Bhatt, and Ndiya Ogba

Subjects
Acute promyelocytic leukemia, medicine.medical_specialty, Myeloid, business.industry, Venetoclax, MEDLINE, Myeloid leukemia, medicine.disease, Clinical trial, Leukemia, chemistry.chemical_compound, medicine.anatomical_structure, Oncology, chemistry, hemic and lymphatic diseases, medicine, Treatment strategy, Intensive care medicine, business
Abstract

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Published
2021
Full Text
View/download PDF

2. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Author

Steven Coutre, Alexander E. Perl, Richard Stone, Vijaya Raj Bhatt, Deniz Peker, Ndiya Ogba, Keith W. Pratz, Frederick R. Appelbaum, Martin S. Tallman, Michael Gary Martin, Thomas W. LeBlanc, Alice S. Mims, Dale L. Bixby, Aric C. Hall, Paul J. Shami, Jeffrey E. Lancet, Marcos de Lima, Stephen A. Strickland, Thomas Prebet, Melanie Fiorella, Meagan A. Jacoby, Lydia J. Hammond, Margaret R. O'Donnell, Guido Marcucci, Jessica K. Altman, Rebecca L. Olin, Daniel A. Pollyea, Gabriel N. Mannis, Matthew J. Wieduwilt, Farhad Ravandi, Eunice S. Wang, Kristina M. Gregory, James M. Foran, and Amir T. Fathi

Subjects
0301 basic medicine, Graft vs Host Disease, Medical Oncology, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, HLA Antigens, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Transplantation, Homologous, Medicine, Aged, business.industry, Histocompatibility Testing, Remission Induction, Age Factors, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Middle Aged, United States, Leukemia, Myeloid, Acute, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Cancer research, business
Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age

Published
2019
Full Text
View/download PDF

3. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Frederick R. Appelbaum, Keith W. Pratz, Steven Coutre, Dale L. Bixby, Michael Gary Martin, Steven D. Gore, Melanie Fiorella, William Blum, Richard Stone, Deniz Peker, Martin S. Tallman, Daniel A. Pollyea, Farhad Ravandi, Camille N. Abboud, Vijaya Raj Bhatt, Jeffrey E. Lancet, Rebecca L. Olin, Matthew J. Wieduwilt, Stephen A. Strickland, Lori J. Maness, Daniel A. Arber, James M. Foran, Aric C. Hall, Guido Marcucci, Patricia Kropf, Eunice S. Wang, Paul J. Shami, Amir T. Fathi, Kristina M. Gregory, Ndiya Ogba, Jessica K. Altman, Marcos de Lima, Joseph O. Moore, and Margaret R. O'Donnell

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Myeloid, MEDLINE, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Disease management (health), neoplasms, Acute leukemia, business.industry, Age Factors, Disease Management, Myeloid leukemia, medicine.disease, Clinical Practice, Transplantation, Leukemia, Myeloid, Acute, Leukemia, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, business
Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results